PDPL

Parenteral Drugs (India) Limited has informed the Exchange regarding Board meeting held on November 13, 2019.

Parenteral Drugs (India) Limited has informed the Exchange regarding 'Revised Compliance Certificate pursuant to Regulation 40(10) of SEBI (LODR) Regulations, 2015'.

Parenteral Drugs (India) Limited has informed the Exchange regarding 'Confirmation Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.'.

Rajratan Exports Private ltd has informed the Exchange regarding reason for encumbrance vide letter dated October 04, 2019 under SEBI ( SAST) Regulations, 2011.

Parenteral Drugs (India) Limited has informed the Exchange regarding Reappointment of Director of the company.

Parenteral Drugs (India) Limited has informed the Exchange regarding Reappointment of Director of the company.

Parenteral Drugs (India) Limited has informed the Exchange regarding voting results of Annual General Meeting held on August 31, 2019

Parenteral Drugs (India) Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 31, 2019

Parenteral Drugs (India) Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 31, 2019

Parenteral Drugs (India) Limited has informed the Exchange regarding 'Newspaper Clippings w.r.t. publication of notice in respect to Annual General Meeting'.

Parenteral Drugs (India) Limited has informed the Exchange regarding 'Parenteral Drugs (India) Limited hereby intimates under Regulation 30 of SEBI (LODR) Regulations, 2015 w.r.t. Notice of forthcoming Annual General Meeting sent to shareholders.'.

Parenteral Drugs (India) Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 31, 2019

Parenteral Drugs (India) Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company will remain closed from August 26, 2019 to August 31, 2019 ( both days inclusive) for the purpose of Annual General Meeting to be held on August 31, 2019.

Parenteral Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended June 30, 2019.

Parenteral Drugs (India) Limited has informed the Exchange regarding Board meeting held on August 05, 2019.

Parenteral Drugs (India) Limited has informed the Exchange regarding 'Parenteral Drugs (India) Limited hereby submits Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018'.

Parenteral Drugs (India) Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Parenteral Drugs (India) Limited has informed the Exchange regarding Disclosure of Related Party Transactions as per Regulation 23 (9) of SEBI (LODR) Regulations, 2019 for the half year ended March 31, 2019

Parenteral Drugs (India) Limited has informed the Exchange regarding Change in Director(s) of the company.

Parenteral Drugs (India) Limited has informed the Exchange regarding the Code of Conduct under SEBI(PIT) Reg., 2015

Parenteral Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended March 31, 2019.

Parenteral Drugs (India) Limited has informed the Exchange regarding Board meeting held on May 30, 2019.

Parenteral Drugs (India) Limited has informed the Exchange regarding Appointment of Mr Vinod Kumar Gupta as Chief Financial Officer of the company w.e.f. April 23, 2019.

The Promoter along with PAC has submitted to the Exchange a copy of Annual Disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers), Regulations, 2011 as on March 31, 2019.

Parenteral Drugs (India) Limited has informed the Exchange regarding Resignation of Mr Balkrishna Vinayak Chaubal as Nominee Director of the company w.e.f. March 27, 2019.

Parenteral Drugs (India) Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Parenteral Drugs (India) Limited has informed the Exchange regarding 'Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding loss of share certificate'.

Parenteral Drugs (India) Limited has informed the Exchange regarding Cessation of Mr Vinod Kumar Gupta as Managing Director of the company w.e.f. February 27, 2019.

Parenteral Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended December 31, 2018.

Parenteral Drugs (India) Limited has informed the Exchange regarding Board meeting held on February 14, 2019 in which Board inter alia considered and approved the Unaudited Financial Results (both Standalone and Consolidated) of the company for the third quarter of the financial year 2018-19 ended on 31st December, 2018.

Significant movement in price has been observed in Parenteral Drugs (India) Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Parenteral Drugs (India) Limited has submitted their response.

Significant movement in price has been observed in Parenteral Drugs (India) Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.

Parenteral Drugs (India) Limited has informed the Exchange regarding Appointment of Ms Suruchi Maheshwari as Company Secretary & Compliance Officer of the company w.e.f. December 06, 2018.

Parenteral Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended September 30, 2018.

Parenteral Drugs (India) Limited has informed the Exchange regarding Board meeting held on November 13, 2018.

Parenteral Drugs (India) Limited has informed the Exchange regarding 'Disclosure of voting results of 34th Annual General Meeting held on 29th September, 2018 along with Scrutinizer's Report.'.

Parenteral Drugs (India) Limited has informed the Exchange regarding 'In compliance of Regulation 30 and Schedule III, Part A, Para A (13) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the 34th Annual General Meeting of the company was held on 29th day of September, 2018 at the Classique Club, Behind Infinity Mall, Link Road, Oshiwara, Andheri (West), Mumbai �� 400053 and the summary proceedings of the 34th AGM are as follows:ORDINARY BUSINESS:1. a. Considered, approved and adopted the Standalone Financial S

Parenteral Drugs (India) Limited has informed the Exchange regarding Resignation of Mrs Aradhana Kulkarni as Company Secretary & Compliance Officer of the company w.e.f. September 16, 2018.

Parenteral Drugs (India) Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed from September 23, 2018 to September 29, 2018 (both days inclusive) for the purpose of Annual General Meeting to be held on September 29, 2018.

Parenteral Drugs (India) Limited has informed the Exchange regarding 'The Board of Directors of the Company at their meeting held on Tuesday, the 14th day of August, 2018 at the Corporate office of the Company has taken on record the change in designation of Shri Manohar Lal Gupta (DIN:0040784) and Shri Anil Mittal(DIN:00039133) from Executive Directors to Non-Executive Directors under promoter category.Kindly take the same on record pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.This is for the information of the exchange and members thereof.'.

Parenteral Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended June 30, 2018.

Parenteral Drugs (India) Limited has informed the Exchange regarding Board meeting held on August 14, 2018.

Parenteral Drugs (India) Limited has informed the Exchange regarding 'This is for the information of the Exchange, its members and general public that pursuant to the right exercised by the one of the preference shareholders of the subsidiary company of the company viz. M/s Infutec Healthcare Limited, it has converted the preference shares into equity shares and resultantly the subsidiary has ceased to be the subsidiary of the company. '.

The Exchange had sought clarification from Parenteral Drugs (India) Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Standalone Reconciliation of Equity not submitted -2. Consolidated Reconciliation of Equity not submitted The response of the Company is enclosed.

The Exchange has sought clarification from Parenteral Drugs (India) Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of Equity not submitted -2. Consolidated Reconciliation of Equity not submitted The response of the Company is awaited.

Parenteral Drugs (India) Limited has informed the Exchange regarding Appointment of Mr Manish Verma as Independent Director of the company w.e.f. Jun 29, 2018.

Parenteral Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended March 31, 2018.

Parenteral Drugs (India) Limited has informed the Exchange regarding Change in Director(s) of the company.

SBICAP Trustee Company Limited has submitted to the Exchange a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Rajratan Exports Private Limited has submitted to the Exchange a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.